ArticleCureus2024
Anaphylaxis to Patent Blue V Dye With Clinical Deterioration Following Administration of Suxamethonium and Sensitisation on Skin Testing to Methylene Blue, Patent Blue V Dye and Suxamethonium.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromuscular blocking drugs (NMBAs) and Patent Blue V dye sodium salt 2.5% (Guerbet, Roissy, France) are frequently implicated in perioperative allergic immunoglobulin E (IgE) mediated anaphylaxis. Most cases of anaphylaxis during surgery occur at induction of anaesthesia, although reactions to vital dyes injected into soft tissues often show a delayed onset. We present the case of a female in her 60s who suffered perioperative anaphylaxis to Patent Blue V dye and possibly suxamethonium during oncological breast surgery. Allergy clinic follow-up confirmed sensitivity to both drugs which may explain the unusual bi-phasic nature of the reaction. Intradermal testing also found cross-sensitivity to methylene blue, but not to other common allergens or NMBAs. This case demonstrates the importance of thorough post-anaphylaxis follow-up and raises the possibility of cross-sensitivity between unrelated compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.